Prolonged hypocalcemic effect by pulmonary delivery of calcitonin loaded poly(methyl vinyl ether maleic acid) bioadhesive nanoparticles

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Varshosaz, J ^a   Minaiyan, M ^a   Forghanian, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; IRON; MALEIC ACID DERIVATIVE; NANOPARTICLE; POLY(METHYL VINYL ETHER MALEIC ACID); SALCATONIN; UNCLASSIFIED DRUG; ZINC ION; BONE DENSITY CONSERVATION AGENT; CALCITONIN; DELAYED RELEASE FORMULATION; MALEIC ACID, METHYL VINYL ETHER POLYMER, CALCIUM SODIUM SALT; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUTION; DRUG STABILITY; GEL ELECTROPHORESIS; HYDROGEN BOND; HYPOCALCEMIA; IN VITRO STUDY; INTRAPULMONARY DRUG ADMINISTRATION; MALE; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; STATIC ELECTRICITY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DELAYED RELEASE FORMULATION; LUNG; MOUSE; PHARMACOLOGY; WISTAR RAT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DELAYED-ACTION PREPARATIONS; HYPOCALCEMIA; LUNG; MALE; MICE; NANOPARTICLES; POLYMERS; RATS, WISTAR;

EID: 84896258708     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/932615     Document Type: Article

References (59)

1. Andreotti G., Méndez B. L., Amodeo P., Castiglione Morelli M. A., Nakamuta H., Motta A., Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic α -helix. Journal of Biological Chemistry 2006 281 34 24193 24203 2-s2.0-33747711389 10.1074/jbc.M603528200 (Pubitemid 44274193)
2. Kline L. W., Longmore G. A., Determination of calcitonin in reptilian serum by heterologous radioimmunoassay. General and Comparative Endocrinology 1986 61 1 1 4 2-s2.0-0022656131 (Pubitemid 16185514)
3. Wendelaar Bonga S. E., Pang P. K. T., Control of calcium regulating hormones in the vertebrates: parathyroid hormone, calcitonin, prolactin, and stanniocalcin. International Review of Cytology 1991 128 139 213 2-s2.0-0025946375
4. Thomas L., Clinical Laboratory Diagnostics 1998 1st Framkfurt, Germany TH-Books Verlagsgesellschaft
5. Endres D. B., Rude R. K., Burtis C. A., AShwood E. R., Mineral and bone metabolism. Textbook of Clinical Chemistry 1999 3rd Philadelphia, Pa, USA W.B Saunders Company 1395 1457
6. Stevenson J. C., Evans I. M. A., Pharmacology and therapeutic use of calcitonin. Drugs 1981 21 4 257 272 2-s2.0-0019860833 (Pubitemid 12206684)
7. Hilton J. M., Dowton M., Houssami S., Sexton P. M., Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. Journal of Endocrinology 2000 166 1 213 226 2-s2.0-0033946363 (Pubitemid 30435891)
8. Sinko P. J., Smith C. L., McWhorter L. T., Stern W., Wagner E., Gilligan J. P., Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. Journal of Pharmaceutical Sciences 1995 84 11 1374 1378 2-s2.0-0028863073 10.1002/jps.2600841120
9. Henriksen K., Bay-Jensen A.-C., Christiansen C., Karsdal M. A., Oral salmon calcitonin pharmacology in osteoporosis. Expert Opinion on Biological Therapy 2010 10 11 1617 1629 2-s2.0-77958486894 10.1517/14712598.2010.526104
10. Shah R. B., Khan M. A., Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: transport mechanism using Caco-2 cell monolayer. AAPS Journal 2004 6 4, article 31 1 5 2-s2.0-33644672831
11. Karsdal M. A., Henriksen K., Arnold M., Christiansen C., Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008 22 3 137 144 2-s2.0-43749087075 10.2165/00063030-200822030-00001 (Pubitemid 351692844)
12. John P., Harald J., Longo D. L., Kasper D. L., Jameson J. L., Fauci A. S., Hauser S. L., Loscalzo J., Disorders of the parathyroid gland and calcium homeostasis. HarriSon'S PrincipleS of Internal Medicine 2008 18th McGraw-Hill
13. Zaidi M., Inzerillo A. M., Moonga B. S., Bevis P. J. R., Huang C.-H., Forty years of calcitonin: where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 2002 30 5 655 663 2-s2.0-0036251168 10.1016/S8756-3282(02) 00688-9 (Pubitemid 34467985)
14. Carney S. L., Calcitonin and human renal calcium and electrolyte transport. Mineral and Electrolyte Metabolism 1997 23 1 43 47 2-s2.0-0031056882 (Pubitemid 27081523)
15. Beveridge T., Niederer W., Nüesch E., Petrin A., Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). Zeitschrift für Gastroenterologie 1976 10 12 15 2-s2.0-0017285522
16. Hinchcliffe M., Jabbal-Gill I., Smith A., Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. Journal of Pharmacy and Pharmacology 2005 57 6 681 687 2-s2.0-18844392068 10.1211/0022357056073 (Pubitemid 40694875)
17. Youn Y. S., Kwon M. J., Na D. H., Chae S. Y., Lee S., Lee K. C., Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. Journal of Controlled Release 2008 125 1 68 75 2-s2.0-36649019135 10.1016/j.jconrel.2007.10.008 (Pubitemid 350198681)
18. Tewes F., Tajber L., Corrigan O. I., Ehrhardt C., Healy A. M., Development and characterisation of soluble polymeric particles for pulmonary peptide delivery. European Journal of Pharmaceutical Sciences 2010 41 2 337 352 2-s2.0-77955843806 10.1016/j.ejps.2010.07.001
19. Huwyler R., Born W., Ohnhaus E. E., Fischer J. A., Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. The American Journal of Physiology 1979 236 1 E15 E19 2-s2.0-0018418005 (Pubitemid 9093518)
20. Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y., pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. Journal of Controlled Release 2004 98 1 1 9 2-s2.0-3042854242 10.1016/j.jconrel.2004.02.001 (Pubitemid 38881602)
21. Lee Y.-H., Sinko P. J., Oral delivery of salmon calcitonin. Advanced Drug Delivery Reviews 2000 42 3 225 238 2-s2.0-0034739238 10.1016/S0169-409X(00) 00063-6 (Pubitemid 30645779)
22. Sinswat P., Tengamnuay P., Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl- β -cyclodextrins. International Journal of Pharmaceutics 2003 257 1-2 15 22 2-s2.0-0037433789 10.1016/S0378-5173(03)00090-5 (Pubitemid 36507028)
23. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., Ikada Y., Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. European Journal of Pharmaceutical Sciences 2001 13 2 179 185 2-s2.0-0035067784 10.1016/S0928-0987(01)00094-X (Pubitemid 32288787)
24. Torres-Lugo M., Peppas N. A., Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000 21 12 1191 1196 2-s2.0-0034087415 10.1016/S0142-9612(00)00011-9 (Pubitemid 30195716)
25. Reginster J.-Y., Jupsin I., Deroisy R., Biquet I., Franchimont N., Franchimont P., Prevention of postmenopausal bone loss by rectal calcitonin. Calcified Tissue International 1995 56 6 539 542 2-s2.0-0029039955 10.1007/BF00298586
26. Gennari C., Gonnelli S., Monaci G., Campagna M. S., Franci B., Pharmacodynamic activity of synthetic salmon calcitonin in osteoporotic patients: comparison between rectal and intramuscular administration. Pilot study. Current Therapeutic Research 1993 53 3 301 308 2-s2.0-0027417211 (Pubitemid 23108909)
27. Petersen S. B., Nielsen L. G., Rahbek U. L., Guldbrandt M., Brayden D. J., Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer. European Journal of Pharmaceutical Sciences 2013 48 4-5 726 734
28. Asano M., Yoshida M., Omichi H., Mashimo T., Okabe K., Yuasa H., Yamanaka H., Morimoto S., Sakakibara H., Biodegradable poly(DL-lactic acid) formulations in a calcitonin delivery system. Biomaterials 1993 14 10 797 799 2-s2.0-0027640937 10.1016/0142-9612(93)90047-6 (Pubitemid 23247509)
29. Millest A. J., Evans J. R., Young J. J., Johnstone D., Sustained release of salmon calcitonin in vivo from lactide: glycolide copolymer depots. Calcified Tissue International 1993 52 5 361 364 2-s2.0-0027221794 (Pubitemid 23124833)
30. Diaz R. V., Llabrés M., Évora C., One-month sustained release microspheres of125I-bovine calcitonin In vitro: in vivo studies. Journal of Controlled Release 1999 59 1 55 62 2-s2.0-0032917367 10.1016/S0168-3659(98) 00179-5 (Pubitemid 29187193)
31. Tasset C., Barette N., Thysman S., Ketelslegers J. M., Lemoine D., Préat V., Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin. Journal of Controlled Release 1995 33 1 23 30 2-s2.0-0028842021 10.1016/0168-3659(94)00060-8
32. van Dijkhuizen-Radersma R., Nicolas H. M., Van de Weert M., Blom M., de Groot K., Bezemer J. M., Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. International Journal of Pharmaceutics 2002 248 1-2 229 237 2-s2.0-0037032442 10.1016/S0378-5173(02) 00458-1 (Pubitemid 35341425)
33. Tewes F., Gobbo O. L., Amaro M. I., Tajber L., Corrigan O. I., Ehrhardt C., Healy A. M., Evaluation of HP β CD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. Molecular Pharmaceutics 2011 8 5 1887 1898 2-s2.0-80053542504 10.1021/mp200231c
34. Yamada K., Control of pulmonary absorption of drugs by various pharmaceutical excipients. Yakugaku Zasshi 2007 127 4 631 641 2-s2.0-34047225620 10.1248/yakushi.127.631 (Pubitemid 46536536)
35. Makhlof A., Werle M., Tozuka Y., Takeuchi H., Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. International Journal of Pharmaceutics 2010 397 1-2 92 95 2-s2.0-77955983828 10.1016/j.ijpharm.2010.07.001
36. Clark A., Kuo M.-C., Newman S., Hirst P., Pitcairn G., Pickford M., A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. Pharmaceutical Research 2008 25 7 1583 1590 2-s2.0-44749083577 10.1007/s11095-008-9547-x
37. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y., Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. Journal of Controlled Release 2005 102 2 373 381 2-s2.0-11844282711 10.1016/j.jconrel.2004.10.010 (Pubitemid 40093760)
38. Yang M., Velaga S., Yamamoto H., Takeuchi H., Kawashima Y., Hovgaard L., van de Weert M., Frokjaer S., Characterisation of salmon calcitonin in spray-dried powder for inhalation: effect of chitosan. International Journal of Pharmaceutics 2007 331 2 176 181 2-s2.0-33846839522 10.1016/j.ijpharm.2006.10. 030 (Pubitemid 46216669)
39. Arbós P., Campanero M. A., Arangoa M. A., Renedo M. J., Irache J. M., Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. Journal of Controlled Release 2003 89 1 19 30 2-s2.0-0242500341 10.1016/S0168-3659(03)00066-X (Pubitemid 36412111)
40. Yoncheva K., Lizarraga E., Irache J. M., Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. European Journal of Pharmaceutical Sciences 2005 24 5 411 419 2-s2.0-15244340396 10.1016/j.ejps.2004.12.002 (Pubitemid 40387255)
41. Gardner C. M., Burke N. A. D., Chu T., Shen F., Potter M. A., Stöver H. D. H., Poly(methyl vinyl ether-alt-maleic acid) polymers for cell encapsulation. Journal of Biomaterials Science 2011 22 16 2127 2145 2-s2.0-80052749767 10.1163/092050610X535149
42. Camacho A. I., Da Costa Martins R., Tamayo I., de Souza J., Lasarte J. J., Mansilla C., Esparza I., Irache J. M., Gamazo C., Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators. Vaccine 2011 29 41 7130 7135 2-s2.0-80052439788 10.1016/j.vaccine.2011.05.072
43. Lin C. W., Huang Y. F., Kannan A. M., Semi-interpenetrating network based on cross-linked poly(vinyl alcohol) and poly(styrene sulfonic acid-co-maleic anhydride) as proton exchange fuel cell membranes. Journal of Power Sources 2007 164 2 449 456 2-s2.0-33846317798 10.1016/j.jpowsour.2006.10.081 (Pubitemid 46116811)
44. Bradford M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976 72 1-2 248 254 2-s2.0-0017184389
45. Zor T., Selinger Z., Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Analytical Biochemistry 1996 236 2 302 308 2-s2.0-0029917011 10.1006/abio.1996.0171 (Pubitemid 26136110)
46. Scheuch G., Siekmeier R., Novel approaches to enhance pulmonary delivery of proteins and peptides. Journal of Physiology and Pharmacology 2007 58 5 615 625 2-s2.0-40449091631 (Pubitemid 351346710)
47. Dailey L. A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T., Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release 2003 86 1 131 144 2-s2.0-0037426696 10.1016/S0168-3659(02) 00370-X (Pubitemid 35461980)
48. Grenha A., Seijo B., Remuñán-López L., Microencapsulated chitosan nanoparticles for lung protein delivery. European Journal of Pharmaceutical Sciences 2005 25 427 437 (Pubitemid 40853870)
49. Shannon R. D., Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallographica 1976 32 75l 767
50. Sakuma S., Ohshima H., Kondo T., Charge distribution in poly(N,N-l-lysinediylterephthaloyl) microcapsule membranes. Journal of Colloid And Interface Science 1989 133 1 253 256 2-s2.0-0001004241
51. Sakuma S., Ohshima H., Kondo T., Binding constants of metal cations to and hamaker constant for poly(N,N-l-lysinediylterephthaloyl) microcapsules. Journal of Colloid And Interface Science 1990 135 2 455 460 2-s2.0-0025401808 (Pubitemid 20696535)
52. Niall H. D., Keutmann H. T., Copp D. H., Potts J. T. Jr., Amino acid sequence of salmon ultimobranchial calcitonin. Proceedings of the National Academy of Sciences of the United States of America 1969 64 2 771 778 2-s2.0-0014583167
53. Peppas N. A., Buri P. A., Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. Journal of Controlled Release 1985 2 257 275 2-s2.0-0022402037 (Pubitemid 16195943)
54. Takeuchi H., Yamamoto H., Niwa T., Hino T., Kawashima Y., Enteral absorption of insulin in rats from mucoadhesive Chitosan-Coated liposomes. Pharmaceutical Research 1996 13 6 896 901 2-s2.0-0029895328 10.1023/A: 1016009313548 (Pubitemid 26227747)
55. Illum L., Farraj N. F., Davis S. S., Chitosan as a novel nasal delivery system for peptide drugs. Pharmaceutical Research 1994 11 8 1186 1189 2-s2.0-0028124642 10.1023/A:1018901302450 (Pubitemid 24259861)
56. Lueßen H. L., de Leeuw B. J., Langemeÿer M. W. E., de Boer A. G., Verhoef J. C., Junginger H. E., Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharmaceutical Research 1996 13 11 1668 1672 2-s2.0-0030453145 10.1023/A:1016488623022 (Pubitemid 26426890)
57. Takeuchi H., Matsui Y., Yamamoto H., Kawashima Y., Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. Journal of Controlled Release 2003 86 2-3 235 242 2-s2.0-0037449495 10.1016/S0168-3659(02)00411-X (Pubitemid 36084273)
58. Takeuchi H., Shimotori Y., Yamamoto H., Hino T., Kawashima Y., Protective effects of chitosan and liposomal formulation for enzymatic degradation of insulin and their absorption promoting effects in intestinal mucous layer. Drug Delivery Systems 1997 12 347 352
59. Morita T., Yamamoto A., Takakura Y., Hashida L. M., Sezaki H., Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various protease inhibitors in rats. Pharmaceutical Research 1994 11 6 909 913 2-s2.0-0028309587 10.1023/A:1018950429341 (Pubitemid 24210630)